Skip to main content
. 2013 Sep 17;4:19–26. doi: 10.2147/POR.S51838

Figure 5.

Figure 5

Number of participants citing each prespecified attribute as the main reason for their overall preference of autoinjector.

Notes: *Novartis Pharma AG, Basel, Switzerland; **Bayer Schering Pharma AG, Berlin, Germany.